Form 4 for JBIO Jade Biosciences, Inc.
Accepted 2023-03-08 00:00:00 ET · period of report 2023-03-06 · accession 0001415889-23-004513 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-03-08 | 2023-03-06 | JBIO | Dake Benjamin T | SEE REMARKS | M - OptEx | $2.05 | +10.3K | 10.3K | New | +$21.0K |
| DM | 2023-03-08 | 2023-03-06 | JBIO | Dake Benjamin T | SEE REMARKS | S - Sale+OE | $23.73 | -10.3K | 0 | -100% | -$244.0K |
| DM | 2023-03-08 | 2023-03-06 | JBIO | Dake Benjamin T | SEE REMARKS | M - OptEx | $0.00 | -10.3K | 185.0K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-06 | M | A | 2,412 | $1.74 | 2,412 | D | — | — | |
| 2 | Common | Common Stock | 2023-03-06 | M | A | 7,870 | $2.14 | 10,282 | D | — | — | |
| 3 | Common | Common Stock | 2023-03-06 | S | D | 10,067 | $23.71 | 215 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.28 to $24.002, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 4 | Common | Common Stock | 2023-03-06 | S | D | 215 | $24.50 | 0 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.30 to $24.96, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 5 | Derivative | Stock Option (Right to Buy) | 2023-03-06 | M | D | 1,018 | $0.00 | 25,460 | D | $2.14 · — to 2031-04-01 | 1,018 Common Stock | (F6) A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. |
| 6 | Derivative | Stock Option (Right to Buy) | 2023-03-06 | M | D | 1,506 | $0.00 | 25,616 | D | $1.74 · — to 2030-09-03 | 1,506 Common Stock | (F5) A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| 7 | Derivative | Stock Option (Right to Buy) | 2023-03-06 | M | D | 906 | $0.00 | 9,055 | D | $1.74 · — to 2030-09-03 | 906 Common Stock | (F4) A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| 8 | Derivative | Stock Option (Right to Buy) | 2023-03-06 | M | D | 6,852 | $0.00 | 185,019 | D | $2.14 · — to 2031-04-01 | 6,852 Common Stock | (F7) A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. |